Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Juan Verdun"'
Autor:
M. Errasti, Juan Verdun, M. Rico, Uxue Zarandona, Fernando Arias de la Vega, Jose Rivadeneira, Juan Ignacio Arraras, Marta Barrondo, Gemma Asin, Koldo Cambra, C. Eito, Miguel Angel Dominguez
Publikováno v:
Quality of Life Research. 23:849-855
Quality of life (QL) is a key outcome for advanced disease cancer patients. The European Organization for Research and Treatment of Cancer (EORTC) has developed the QLQ-C15-PAL questionnaire, a short version of the QLQ-C30 for palliative care. The ai
Autor:
Maria Jose Lecumberri, Maite Martínez, Esther Aznarez, Ruth Vera, Susana De La Cruz, Irene Gil, Ainhoa Castillo, Patricia Ochoa, D. Guerrero, Elena Mata, Juan Verdun, Irene Hernandez, Berta Hernandez, Jose Rivadeneira, Idoia Morilla, Antonio Viudez, Lucia Teijeira
Publikováno v:
Journal of Clinical Oncology. 32:e19158-e19158
e19158 Background: Crizotinib is an oral tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and has been approved in several countries for treatment of advanced ALK-positive no...
Autor:
Javier Suárez, Ruth Vera, Marta Montes, D. Guerrero, Angela Fernandez de Lascoiti, José Antonio Rivadeneira Cabana, Maria Luisa Gomez Dorronsoro, Miguel Angel Ciga Lozano, Irene Hernandez, Antonio Tarifa, Antonio Viudez, Juan Verdun
Publikováno v:
Annals of Oncology. 24:iv117
e14589 Background: Tejpar et al (JCO2012; 30(29):3570-7) showed that patients with aCRC and Gly13D kras mutation experienced worse response rate with chemotherapy alone compared to those with other kras mutations. This retrospective study analyzes di
Autor:
Antonio Viudez, Antonio Tarifa, Juan Verdun, Cruz Zazpe, Lucia Teijeira, María Luisa Antelo, Virginia Arrazubi, M. J. Uriz, Ruth Vera
Publikováno v:
Journal of Clinical Oncology. 29:e14146-e14146
e14146 Background: The presence of baseline ≥ 3 (CTCs) in 7.5 mL of blood is predictive of a poor outcome in advanced colorectal cancer (JCO, 26;19: 3213-3221, 2008). The aim of this prospectively....
Autor:
A. Viudez, Virginia Arrazubi, Lucia Teijeira, M. L. Gomez Dorronsoro, Ruth Vera, D. Guerrero, Gemma Asin, Juan Verdun, Fernando Arias, Javier Suárez, E. Balen
Publikováno v:
Journal of Clinical Oncology. 29:e14080-e14080
e14080 Background: Neoadjuvant concomitant fluoropyrimidine-based chemotherapy plus radiotherapy is considered a standard approach for LARC. SNPs of TS, the target for fluoropyrimidines, are recogn...